` EQ (Equillium Inc) vs S&P 500 Comparison - Alpha Spread

EQ
vs
S&P 500

Over the past 12 months, EQ has underperformed S&P 500, delivering a return of -53% compared to the S&P 500's +13% growth.

Stocks Performance
EQ vs S&P 500

Loading
EQ
S&P 500
Add Stock

Performance Gap
EQ vs S&P 500

Loading
EQ
S&P 500
Difference
www.alphaspread.com

Performance By Year
EQ vs S&P 500

Loading
EQ
S&P 500
Add Stock

Competitors Performance
Equillium Inc vs Peers

Equillium Inc
Glance View

Market Cap
14.8m USD
Industry
Biotechnology

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

EQ Intrinsic Value
2.8979 USD
Undervaluation 86%
Intrinsic Value
Price
Back to Top